Drug Profile

CBT 007

Alternative Names: CBT-007

Latest Information Update: 13 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cloudbreak Pharma
Class Antiglaucomas; Eye disorder therapies
Mechanism of Action Fibroblast growth factor inhibitors; Vascular endothelial growth factors inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

13 Nov 2025 CBT 007 is still in preclinical trials for Glaucoma in USA (Cloudbreak Pharma pipeline, November 2025)
28 Sep 2025 No recent reports of development identified for preclinical development in Glaucoma in USA (Ophthalmic)
27 Aug 2021 Cloudbreak Pharma has patent protection for ophthalmic drug candidates (Cloudbreak Pharma website, August 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com